Clinical Trials Sponsored by Kibo Nam

Total 650 results

Kibo Nam
National Cancer Institute (NCI)

Recruiting

Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Kibow Pharma

Completed

Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure (Probiotics)

Chronic Kidney Failure

United States
Kibow Pharma

Recruiting

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study

Chronic Kidney Disease stage4

United States
Kibow Pharma

Recruiting

Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV (CKD)

Chronic Kidney Disease stage4

United States
KBio Inc

Completed

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

Covid19

United States, Canada
KBio Inc

Completed

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Influenza

United States
Zibo Central Hospital

Recruiting

Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy

Adverse Effect of Cardiovascular Medications (Diagnosis)

China
Kilo Health
Citruslabs

Active, not recruiting

A Single-Group Study to Examine the Efficacy of a Gut Health Supplement to Increase Metabolism, Improve Gut Health, and Support Weight Management

Weight Loss | Metabolism | Energy | Gut Health

United States
Zibo Central Hospital

Unknown

Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment

Atherosclerosis

China
Kibi International University

Unknown

iPad Application-based Intervention for Post-stroke Depression

Post-stroke Depression

Japan
Kibi International University

Completed

Smartphone Intervention for Subthreshold Depression

Subthreshold Depression

Japan
Kibi International University

Completed

Immediate Effect of Subliminal Priming With Subliminal Reward Stimuli on Standing Balance in Healthy Young Adults

Healthy
Zibo Central Hospital

Recruiting

The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy

Carotid Artery Diseases

China
Kibi International University

Completed

Study Protocol for a Smartphone Application-based Intervention for Subthreshold Depression

Subthreshold Depression

Japan
Kibi International University

Completed

Effect of Positive-word Stimuli on the Limits of Stability During Multi-direction Reach Operation in Standing Position

Healthy

Japan
Kibow Pharma
Thomas Jefferson University

Completed

Observational Study of Kibow Biotics in Dialysis Patients

Chronic Kidney Failure

United States
Kibow Pharma
Thomas Jefferson University

Completed

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients

Chronic Kidney Failure

United States
Kyu Nam Park

Unknown

A Prospective, Multicenter Registry With Targeted Temperature Management After Out-of-hospital Cardiac Arrest in Korea

Out-of-Hospital Cardiac Arrest

Korea, Republic of
Qianfoshan Hospital
Zibo Central Hospital

Recruiting

TEE Monitoring and the Incidence of Postoperative Acute Kidney Injury in Coronary Artery Bypass Grafting

Coronary Artery Bypass Surgery

China
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

Hyperlipemia

China
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

Healthy Volunteers

Australia
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

Health Volunteer

Australia
Suzhou Kebo Ruijun Biotechnology Co., Ltd

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Pharma VAM

Unknown

Clinical Study in the Treatment of Patients With COVID-19

COVID-19

Russian Federation
Shenzhen Aibo Medical Robot Co., LTD

Not yet recruiting

A Clinical Study for the Pan-vascular Interventional Robotic System

Percutaneous Coronary Intervention | Pan-vascular Interventional Robotic System

China
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Study of RBD1016 in CHB Participants

Chronic Hepatitis b

Sweden
Suzhou Kebo Ruijun Biotechnology Co., Ltd

Recruiting

A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors or Lymphomas

China
Suzhou Ribo Life Science Co. Ltd.

Completed

A Single and Repeated Dose Escalation of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Chronic Hepatitis b

China
KBio Inc
Eastern Virginia Medical School

Completed

An Exploratory Study of ZB-06 as a Vaginal Contraceptive Film

Contraception

United States
Suzhou Ribo Life Science Co. Ltd.

Completed

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

Healthy Volunteers

Australia
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

Diabetes Mellitus

Australia, New Zealand
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Australia, Belgium, France, Germany, Hong Kong, Poland, Puerto Rico, United Kingdom
NGM Biopharmaceuticals, Inc

Active, not recruiting

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Melanoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Metastatic Castration-resistant Prostate Cancer | Head Neck Squamous Cell Carcinoma

United States
NGM Biopharmaceuticals, Inc

Terminated

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

SARS-CoV-2 Infection

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Healthy Male

United States
NGM Biopharmaceuticals, Inc

Completed

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
NGM Biopharmaceuticals, Inc

Completed

Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

United States, France, Netherlands, United Kingdom
NGM Biopharmaceuticals, Inc

Completed

Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

Functional Constipation

United States
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Impaired Hepatic Function

United States
NGM Biopharmaceuticals, Inc

Completed

Study of NGM395 in Adult Participants

Obesity | NAFLD

Australia
NGM Biopharmaceuticals, Inc

Completed

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Cachexia

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of NGM313 in Obese Participants

Obese

United States
Sen-Jam Pharmaceutical

Completed

Safety and Efficacy of a Combination Product for the Prevention of Veisalgia

Veisalgia
NGM Biopharmaceuticals, Inc

Completed

Phase 1 Study of NGM313 in Healthy Adult Participants

Obesity

Australia
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
NGM Biopharmaceuticals, Inc

Completed

A Study of NGM621 in Participants With Geographic Atrophy (CATALINA)

Geographic Atrophy

United States
NGM Biopharmaceuticals, Inc

Completed

Study of NGM621 in Participants With Geographic Atrophy

Geographic Atrophy

United States
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Impaired Renal Function

United States

Clinical Trials Sponsored by Kibo Nam

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations